Esophageal Cancer Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharma, Amgen, AstraZeneca, Symphogen, Hoffmann-La Roche

The Key Esophageal Cancer Companies in the market include - Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharmaceuticals, Amgen, Jazz Pharmaceuticals, Zymeworks, BeiGene, AstraZeneca, Symphogen, Hoffmann-La Roche, Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shanghai Henlius Biotech, CStone Pharmaceuticals, Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., and others.

DelveInsight's "Esophageal Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Esophageal Cancer, historical and forecasted epidemiology as well as the Esophageal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Esophageal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Esophageal Cancer Market Forecast [https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Esophageal Cancer Market Report:

*
Among the 7MM countries Esophageal Cancer market size was valued ~USD 1,000 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
Within the EU4 and the UK, the UK held the largest share of the esophageal cancer market, representing approximately 36% of the total, with Germany ranking second.

*
Among the seven major markets, Japan, accounted for the highest number of total diagnosed incident cases (~26,000), followed by the United States, in the 2023.

*
In 2023, as per the age-specific cases, the 65 and above segment accounted for the highest number of cases of esophageal cancer. In contrast, the

*
In 2023, males represented 80% of esophageal cancer cases in the United States, while females accounted for 20%.

*
As per the Histology-specific incident cases of esophageal cancer, non-squamous esophageal cancer cases accounted for ~12,500 cases, whereas ~7,300 cases of squamous esophageal cancer, were found in 2023, in the United States.

*
Among the EU4 and the UK, the UK accounted for the highest number of incident diagnosed cases of esophageal cancer.

*
TP53 was the most common mutation found in approximately 80% of the total diagnosed incident cases, in the seven major markets, in 2023.

*
Key Esophageal Cancer Companies: Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharmaceuticals, Amgen, Jazz Pharmaceuticals, Zymeworks, BeiGene, AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences, and others

*
Key Esophageal Cancer Therapies: CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, Zanidatamab, Tislelizumab, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab, SI B001,Apatinib, and others

*
The Esophageal Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Esophageal Cancer pipeline products will significantly revolutionize the Esophageal Cancer market dynamics.

Esophageal Cancer Overview

Esophageal cancer refers to the development of cancerous cells in the esophagus, the tube that carries food from the mouth to the stomach. The esophagus is part of the digestive system and is located between the throat (pharynx) and the stomach. Esophageal cancer can occur when the cells lining the esophagus undergo abnormal changes and start growing uncontrollably.

Get a Free sample for the Esophageal Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/esophageal-cancer-market [https://www.delveinsight.com/report-store/esophageal-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Esophageal Cancer Epidemiology

The Esophageal Cancer epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Esophageal Cancer Epidemiology Segmentation:

The Esophageal Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Esophageal Cancer

*
Prevalent Cases of Esophageal Cancer by severity

*
Gender-specific Prevalence of Esophageal Cancer

*
Diagnosed Cases of Episodic and Chronic Esophageal Cancer

Download the report to understand which factors are driving Esophageal Cancer epidemiology trends @ Esophageal Cancer Epidemiology Forecast [https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Esophageal Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Esophageal Cancer market or expected to get launched during the study period. The analysis covers Esophageal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Esophageal Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Esophageal Cancer Therapies and Key Companies

*
CYRAMZA (ramucirumab): Eli Lilly and Company

*
VITRAKVI (larotrectinib): Bayer

*
Zanidatamab: Zymeworks/Jazz Pharmaceuticals

*
Bemarituzumab: Amgen

*
Zanidatamab: Jazz Pharmaceuticals/Zymeworks

*
Tislelizumab: BeiGene

*
Durvalumab: Celgene/MedImmune

*
Tucatinib: Seagen

*
M1231: Merck KGaA

*
APX 005M: Apexigen

*
Erdafitinib: Janssen Research & Development, LLC

*
Margetuximab: MacroGenics

*
AN-0025: Adlai Nortye

Discover more about therapies set to grab major Esophageal Cancer market share @ Esophageal Cancer Treatment Landscape [https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Esophageal Cancer Market Strengths

*
The emerging asset zanidatamab has a novel mechanism of action, where it uses biparatropic binding to bind to two distinct HER2 epitopes: ECD2 and ECD4. This would end up providing HER2-positive patients with a novel treatment option with increased efficacy.

*
Innovations in the diagnostic landscape of esophageal cancer is set to help diagnose the disease earlier, significantly improving prognosis of its treatment.

Esophageal Cancer Market Opportunities

*
The emerging asset zanidatamab has a novel mechanism of action, which makes it a promising asset. But the drug is a treatment option for only HER2 positive patients. Thus, there is a huge opportunity for drugs having novel mechanism of action to enter the treatment landscape and address a larger patient pool.

*
Identifying additional potentially targetable biomarkers and their effective targeting by novel molecules could significantly improve patient outcomes in patients with low expression of known targetable biomarkers like PD-L1 and HER2.

Scope of the Esophageal Cancer Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Esophageal Cancer Companies: Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharmaceuticals, Amgen, AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences, and others

*
Key Esophageal Cancer Therapies: CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, Zanidatamab, Tislelizumab, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab, SI B001,Apatinib, and others

*
Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies

*
Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Esophageal Cancer Unmet Needs, KOL's views, Analyst's views, Esophageal Cancer Market Access and Reimbursement

To know more about Esophageal Cancer companies working in the treatment market, visit @ Esophageal Cancer Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Esophageal Cancer Market Report Introduction

2. Executive Summary for Esophageal Cancer

3. SWOT analysis of Esophageal Cancer

4. Esophageal Cancer Patient Share (%) Overview at a Glance

5. Esophageal Cancer Market Overview at a Glance

6. Esophageal Cancer Disease Background and Overview

7. Esophageal Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Esophageal Cancer

9. Esophageal Cancer Current Treatment and Medical Practices

10. Esophageal Cancer Unmet Needs

11. Esophageal Cancer Emerging Therapies

12. Esophageal Cancer Market Outlook

13. Country-Wise Esophageal Cancer Market Analysis (2020-2034)

14. Esophageal Cancer Market Access and Reimbursement of Therapies

15. Esophageal Cancer Market Drivers

16. Esophageal Cancer Market Barriers

17. Esophageal Cancer Appendix

18. Esophageal Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esophageal-cancer-market-to-evolve-rapidly-over-the-next-decade-by-2034-delveinsight-observes-eli-lilly-and-company-bayer-zymeworks-jazz-pharma-amgen-astrazeneca-symphogen-hoffmannla-roche]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.